These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2124499)

  • 21. Factor VIII concentrate infusion in patients with haemophilia results in decreased von Willebrand factor and ADAMTS-13 activity.
    van Bladel ER; Tuinenburg A; Roest M; de Groot PG; Schutgens RE
    Haemophilia; 2014 Jan; 20(1):92-8. PubMed ID: 24028772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A.
    Mullah-Ali AM; Chan AK; Lillicrap D; Decker K; Seroski W; Moffat K; Walker I; Pai MK
    Haemophilia; 2009 Nov; 15(6):1258-61. PubMed ID: 19563498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autosomal recessive transmission of hemophilia A due to a von Willebrand factor mutation.
    Wise RJ; Ewenstein BM; Gorlin J; Narins SC; Jesson M; Handin RI
    Hum Genet; 1993 May; 91(4):367-72. PubMed ID: 8500791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1.
    Schneppenheim R; Budde U; Krey S; Drewke E; Bergmann F; Lechler E; Oldenburg J; Schwaab R
    Thromb Haemost; 1996 Oct; 76(4):598-602. PubMed ID: 8903002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
    Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
    Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical phenotype in genetically confirmed von Willebrand disease type 2N patients reflects a haemophilia A phenotype.
    van Meegeren ME; Mancini TL; Schoormans SC; van Haren BJ; van Duren C; Diekstra A; Laros-van Gorkom BA; Brons PP; Simons A; Hoefsloot L; van Heerde WL
    Haemophilia; 2015 Sep; 21(5):e375-83. PubMed ID: 26207643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemophilia A or von Willebrand disease?
    Batlle J; Blanco-Lopez MJ; Domenech M; Baiget M; Rocha R; Lopez-Fernandez MF
    Ann Hematol; 1994 Dec; 69(6):317-9. PubMed ID: 7993941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterisation of type 2N von Willebrand disease using phenotypic and molecular techniques.
    Nesbitt IM; Goodeve AC; Guilliatt AM; Makris M; Preston FE; Peake IR
    Thromb Haemost; 1996 Jun; 75(6):959-64. PubMed ID: 8822593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
    Swystun LL; Ogiwara K; Rawley O; Brown C; Georgescu I; Hopman W; Labarque V; Male C; Thom K; Blanchette VS; Carcao MD; Lillicrap D
    Blood; 2019 Sep; 134(11):880-891. PubMed ID: 31350267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory.
    Zhukov O; Popov J; Ramos R; Vause C; Ruden S; Sferruzza A; Dlott J; Sahud M
    Haemophilia; 2009 May; 15(3):788-96. PubMed ID: 19298374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The factor VIII:C/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: A retrospective cohort study.
    Trossaert M; Graveleau J; Thiercelin-Legrand MF; Sigaud M; Guerrero F; Neel A; Fouassier M; Sailler L; Chauveau D; Ternisien C; Huart A; Gillet B; Hamidou M; Bene MC; Voisin S
    Haemophilia; 2019 May; 25(3):527-534. PubMed ID: 31050100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo evaluation of a factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Favourable effects of heating on the von Willebrand factor.
    Mazurier C; de Romeuf C; Parquet-Gernez A; Jorieux S; Goudemand M
    Vox Sang; 1987; 52(4):265-71. PubMed ID: 3114955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
    Hubbard AR; Rigsby P; Barrowcliffe TW
    Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion.
    Casonato A; Pontara E; Boscaro M; Dannhauser D; Sartori MT; Girolami A
    Haematologia (Budap); 1993; 25(1):57-67. PubMed ID: 8339998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.